HbA1c and Hypoglycemia Reductions at 24 and 52 Weeks With Sotagliflozin in Combination With Insulin in Adults With Type 1 Diabetes: The European inTandem2 Study

Cardiovascular and Metabolic Risk

HbA_1c and Hypoglycemia Reductions at 24 and 52 Weeks With Sotagliflozin in Combination With Insulin in Adults With Type 1 Diabetes: The European inTandem2 Study

¹Department of Diabetes, Endocrinology, and Clinical Research, Children’s and Youth Hospital Auf der Bult, Hannover Medical School, Hannover, Germany
²L’institut du thorax, Department of Endocrinology, CHU Nantes, CIC 1413, INSERM, Nantes, France
³Lexicon Pharmaceuticals, Inc., The Woodlands, TX
⁴Department of Internal Medicine, Kantonsspital St. Gallen, St. Gallen, Switzerland
⁵Diabetes Outpatient Clinic, Health Center South, Vienna, Austria
⁶Mossakowski Medical Research Center, Polish Academy of Sciences, Warsaw, Poland
⁷Department of Pediatrics, Baylor College of Medicine and Texas Children’s Hospital, Houston, TX
⁸Department of Internal Medicine, Division of Cardiology, University of Texas Southwestern Medical Center, Dallas, TX
⁹University of Southern California Keck School of Medicine, Los Angeles, CA